諾和諾德 (Novo Nordisk) (NVO) 在 3 期減肥治療結果令人失望後，其價值損失了 20% 以上

上週，諾和諾德（NVO）市值損失超過五分之一。生技投資人對禮來公司（LLY）的臨床數據結果反應過度。

Novo Nordisk (NVO) shares dropped sharply last week after the biotechnology company reported Phase 3 results of its next-generation weight loss therapy.

生技公司諾和諾德 (NVO) 公佈其下一代減肥療法的第三階段結果後，該公司股價上周大幅下跌。

Investors were left disappointed by the readout, which showed that CagriSemi met the primary endpoint but achieved a weight loss of only up to around 20% in subjects over 68 weeks. This is slightly below that offered by Eli Lilly's (LLY) drug, where patients may lose around 23%.

投資者對結果感到失望，結果顯示 CagriSemi 達到了主要終點，但在 68 週內受試者的體重僅減輕了 20% 左右。這略低於禮來公司 (LLY) 藥物提供的效果，患者可能損失約 23%。

Analysts had expected CagriSemi to achieve a weight loss of nearly 25%.

分析師先前預期CagriSemi將實現近25%的減重。

Now, investors are speculating that Eli Lilly and Viking Therapeutics (VKTX) will benefit from Novo's clinical readout.

現在，投資者猜測禮來公司和 Viking Therapeutics (VKTX) 將從 Novo 的臨床結果中受益。

In the retail sector, Nike (NKE) shares closed at around $77.00 after the company posted second-quarter results.

在零售領域，耐吉 (NKE) 公佈第二季業績後，股價收在 77.00 美元左右。

The firm highlighted the need for shareholder patience as it develops its turnaround plan.

該公司強調，在製定扭虧為盈計畫時，股東需要保持耐心。

CEO Elliot Hill noted that the company will prioritize the digital channel. More importantly, it will focus on the sports market while drawing down its excess inventory.

執行長艾利奧特·希爾指出，公司將優先考慮數位管道。更重要的是，它將專注於運動市場，同時減少多餘的庫存。

Bitcoin (BTC-USD) fell sharply from the $105,000 - $108,000 highs seen last week and traded at around $97,290 in response to the Fed signaling fewer interest rate cuts in 2025.

由於聯準會暗示 2025 年降息幅度較小，比特幣（BTC-USD）從上週 105,000 美元至 108,000 美元的高點大幅下跌，交易價格約為 97,290 美元。

Higher interest rate levels increase the attractiveness of the U.S. dollar, which decreases demand for gold and bitcoin.

較高的利率水準增加了美元的吸引力，從而減少了對黃金和比特幣的需求。

However, once the government averts a shutdown, we could see bitcoin bouncing back and finding new record highs.

然而，一旦政府避免關閉，我們可能會看到比特幣反彈並創下新的歷史高點。